At a glance
- Originator Kurobe LLC
- Class Antibacterials; Glycopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Conjunctivitis
Most Recent Events
- 16 Feb 2022 No development reported - Phase-III for Conjunctivitis in USA (Ophthalmic)
- 01 May 2015 Phase-III clinical trials in Conjunctivitis in USA (Ophthalmic) (NCT02432807)